Chip­ping away at Gilead­'s HIV em­pire, GSK's Vi­iV sub­mits NDA for 2-drug HIV reg­i­men -- play­ing vouch­er card for speedy FDA re­view

GSK’s am­bi­tion to cap­ture a big­ger piece of the HIV drug mar­ket from US ri­val Gilead con­tin­ues as its ma­jor­i­ty-owned Vi­iV Health­care sub­mit­ted an ap­pli­ca­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER